Safety and Performance Study of the Nyxoah SAT System for Treating OSA
Primary Purpose
Obstructive Sleep Apnea
Status
Terminated
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Nyxoah SAT system
Sponsored by
About this trial
This is an interventional treatment trial for Obstructive Sleep Apnea
Eligibility Criteria
Inclusion Criteria:
- Diagnosed with moderate to severe Obstructive Sleep Apnea
- Have failed or have not tolerated CPAP treatment
- Willing and capable of providing informed consent
- Willing and capable of returning to all follow-up visits and sleep studies, including evaluation procedures and filling out questionnaires
Exclusion Criteria:
- BMI limits
- Subjects with complete concentric collapse at the soft palate level per endoscopy
Sites / Locations
- Antwerp University Hospital
- Universitäts-HNO-Klinik Mannheim
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Nyxoah SAT therapy
Arm Description
Outcomes
Primary Outcome Measures
Incidence of serious device related adverse events
Mean change of AHI (Apnea-Hypopnea Index) measured by in-lab polysomnography (PSG) from baseline measurement to 6-months post-implantation
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02312479
Brief Title
Safety and Performance Study of the Nyxoah SAT System for Treating OSA
Official Title
Safety and Performance Study of the Use of the Nyxoah SAT System for the Treatment of Obstructive Sleep Apnea
Study Type
Interventional
2. Study Status
Record Verification Date
September 2016
Overall Recruitment Status
Terminated
Study Start Date
December 2014 (undefined)
Primary Completion Date
November 2015 (Actual)
Study Completion Date
April 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nyxoah S.A.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
A prospective open-label, single treatment study to assess the safety and the performance of the Nyxoah SAT system for the treatment of Obstructive Sleep Apnea
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obstructive Sleep Apnea
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
6 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Nyxoah SAT therapy
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Nyxoah SAT system
Intervention Description
The Nyxoah SAT system is comprised of an implantable nerve stimulator implanted over one of the tongue muscles via a minimally invasive procedure. Stimulation of the Hypoglossal nerves causes the tongue muscles to contract, thus maintaining an open airway during sleep.
Primary Outcome Measure Information:
Title
Incidence of serious device related adverse events
Time Frame
6-months post-implantation
Title
Mean change of AHI (Apnea-Hypopnea Index) measured by in-lab polysomnography (PSG) from baseline measurement to 6-months post-implantation
Time Frame
6-months post-implantation
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosed with moderate to severe Obstructive Sleep Apnea
Have failed or have not tolerated CPAP treatment
Willing and capable of providing informed consent
Willing and capable of returning to all follow-up visits and sleep studies, including evaluation procedures and filling out questionnaires
Exclusion Criteria:
BMI limits
Subjects with complete concentric collapse at the soft palate level per endoscopy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joachim T Maurer, OA Dr. med.
Organizational Affiliation
Universitäts-HNO-Klinik Mannheim
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Evert Hamans, PhD Dr.
Organizational Affiliation
Universiteit Antwerpen
Official's Role
Principal Investigator
Facility Information:
Facility Name
Antwerp University Hospital
City
Edegem
Country
Belgium
Facility Name
Universitäts-HNO-Klinik Mannheim
City
Mannheim
Country
Germany
12. IPD Sharing Statement
Learn more about this trial
Safety and Performance Study of the Nyxoah SAT System for Treating OSA
We'll reach out to this number within 24 hrs